BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 10735336)

  • 21. Pharmacologic prevention of osteoporotic fractures.
    Zizic TM
    Am Fam Physician; 2004 Oct; 70(7):1293-300. PubMed ID: 15508540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evidence of raloxifene on postmenopausal osteoporosis].
    Okano H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():374-80. PubMed ID: 18161135
    [No Abstract]   [Full Text] [Related]  

  • 23. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density.
    Riggs BL; Melton LJ
    J Bone Miner Res; 2002 Jan; 17(1):11-4. PubMed ID: 11771656
    [No Abstract]   [Full Text] [Related]  

  • 24. [Delaying degeneration or promoting regeneration. 2 successful strategies in osteoporosis].
    MMW Fortschr Med; 2004 Mar; 146(10):46. PubMed ID: 15347088
    [No Abstract]   [Full Text] [Related]  

  • 25. Raloxifene: new preparation. Not better than oestrogen.
    Prescrire Int; 1999 Dec; 8(44):165-7. PubMed ID: 11503811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [SERMs for treatment of osteoporosis: state-of-the-art and perspectives].
    Legrand E; Hoppé E; Chappard D; Audran M
    Gynecol Obstet Fertil; 2006 May; 34(5):423-8. PubMed ID: 16697240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Who are the candidates for the treatment by raloxifen ?].
    Hagino H
    Clin Calcium; 2004 Oct; 14(10):111-3. PubMed ID: 15577141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
    Higuchi T; Mizunuma H
    Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Third-generation SERMs may face uphill battle.
    Schmidt C
    J Natl Cancer Inst; 2010 Nov; 102(22):1690-2. PubMed ID: 21060064
    [No Abstract]   [Full Text] [Related]  

  • 30. [Role of estrogen and selective estrogen receptor modulators in anti-aging].
    Ohta H
    Clin Calcium; 2008 Jul; 18(7):986-94. PubMed ID: 18591752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
    Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
    Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical experience with raloxifene].
    Szúcs J; Pávó I; Jurida N
    Orv Hetil; 2000 Jan; 141(5):237-40. PubMed ID: 10697982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alendronic acid in primary prevention: new indication. No reduction in fracture risk.
    Prescrire Int; 2000 Jun; 9(47):70-2. PubMed ID: 11010741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lasofoxifene in postmenopausal women with osteoporosis.
    Cummings SR; Ensrud K; Delmas PD; LaCroix AZ; Vukicevic S; Reid DM; Goldstein S; Sriram U; Lee A; Thompson J; Armstrong RA; Thompson DD; Powles T; Zanchetta J; Kendler D; Neven P; Eastell R;
    N Engl J Med; 2010 Feb; 362(8):686-96. PubMed ID: 20181970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fewer fractures with raloxifene.
    Feinberg AW
    Health News; 1999 Oct; 5(12):3. PubMed ID: 10536528
    [No Abstract]   [Full Text] [Related]  

  • 36. [SERM for early osteoporosis therapy. Risk for first spinal fracture reduced to half].
    MMW Fortschr Med; 2003 May; 145(22):57. PubMed ID: 12866287
    [No Abstract]   [Full Text] [Related]  

  • 37. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
    Ohta H
    Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Relationship between changes in biochemical markers of bone turnover and prediction value of fracture risk].
    Cyaki O
    Clin Calcium; 2004 Oct; 14(10):39-46. PubMed ID: 15577130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defining the role of raloxifene for the prevention of breast cancer.
    Kalidas M; Hilsenbeck S; Brown P
    J Natl Cancer Inst; 2004 Dec; 96(23):1731-3. PubMed ID: 15572750
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effects of SERM on the cardiovascular system].
    Okazaki R
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():381-5. PubMed ID: 18161136
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.